Your browser doesn't support javascript.
Engineering the next generation of cell-based therapeutics.
Bashor, Caleb J; Hilton, Isaac B; Bandukwala, Hozefa; Smith, Devyn M; Veiseh, Omid.
  • Bashor CJ; Department of Bioengineering, Rice University, Houston, TX, USA. caleb.bashor@rice.edu.
  • Hilton IB; Department of Biosciences, Rice University, Houston, TX, USA. caleb.bashor@rice.edu.
  • Bandukwala H; Department of Bioengineering, Rice University, Houston, TX, USA. isaac.hilton@rice.edu.
  • Smith DM; Department of Biosciences, Rice University, Houston, TX, USA. isaac.hilton@rice.edu.
  • Veiseh O; Sigilon Therapeutics, Cambridge, MA, USA.
Nat Rev Drug Discov ; 21(9): 655-675, 2022 09.
Article in English | MEDLINE | ID: covidwho-2062224
ABSTRACT
Cell-based therapeutics are an emerging modality with the potential to treat many currently intractable diseases through uniquely powerful modes of action. Despite notable recent clinical and commercial successes, cell-based therapies continue to face numerous challenges that limit their widespread translation and commercialization, including identification of the appropriate cell source, generation of a sufficiently viable, potent and safe product that meets patient- and disease-specific needs, and the development of scalable manufacturing processes. These hurdles are being addressed through the use of cutting-edge basic research driven by next-generation engineering approaches, including genome and epigenome editing, synthetic biology and the use of biomaterials.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cell- and Tissue-Based Therapy / Gene Editing Type of study: Prognostic study Limits: Humans Language: English Journal: Nat Rev Drug Discov Journal subject: Pharmacology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: S41573-022-00476-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cell- and Tissue-Based Therapy / Gene Editing Type of study: Prognostic study Limits: Humans Language: English Journal: Nat Rev Drug Discov Journal subject: Pharmacology / Drug Therapy Year: 2022 Document Type: Article Affiliation country: S41573-022-00476-6